107 related articles for article (PubMed ID: 15846074)
1. Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228.
Hirokawa Y; Nakajima H; Hanemann CO; Kurtz A; Frahm S; Mautner V; Maruta H
Cancer Biol Ther; 2005 Apr; 4(4):379-81. PubMed ID: 15846074
[TBL] [Abstract][Full Text] [Related]
2. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
3. Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice.
Hirokawa Y; Nheu T; Grimm K; Mautner V; Maeda S; Yoshida M; Komiyama K; Maruta H
Cancer Biol Ther; 2006 Mar; 5(3):305-9. PubMed ID: 16418572
[TBL] [Abstract][Full Text] [Related]
4. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Hirokawa Y; Arnold M; Nakajima H; Zalcberg J; Maruta H
Cancer Biol Ther; 2005 Sep; 4(9):956-60. PubMed ID: 16082189
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
[TBL] [Abstract][Full Text] [Related]
6. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
[TBL] [Abstract][Full Text] [Related]
7. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
[TBL] [Abstract][Full Text] [Related]
8. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.
Demestre M; Messerli SM; Celli N; Shahhossini M; Kluwe L; Mautner V; Maruta H
Phytother Res; 2009 Feb; 23(2):226-30. PubMed ID: 18726924
[TBL] [Abstract][Full Text] [Related]
9. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
Kwon HJ; Kim MS; Kim MJ; Nakajima H; Kim KW
Int J Cancer; 2002 Jan; 97(3):290-6. PubMed ID: 11774279
[TBL] [Abstract][Full Text] [Related]
11. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo].
Xu DB; Wang YL; Yue Y; Wu SC; Ding H
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477
[TBL] [Abstract][Full Text] [Related]
13. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
[TBL] [Abstract][Full Text] [Related]
15. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.
Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Cancer Lett; 2003 Jun; 195(2):161-8. PubMed ID: 12767524
[TBL] [Abstract][Full Text] [Related]
16. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
Karam JA; Fan J; Stanfield J; Richer E; Benaim EA; Frenkel E; Antich P; Sagalowsky AI; Mason RP; Hsieh JT
Int J Cancer; 2007 Apr; 120(8):1795-802. PubMed ID: 17230511
[TBL] [Abstract][Full Text] [Related]
17. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Ito T; Ouchida M; Morimoto Y; Yoshida A; Jitsumori Y; Ozaki T; Sonobe H; Inoue H; Shimizu K
Cancer Lett; 2005 Jun; 224(2):311-9. PubMed ID: 15914281
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
Cao H; Stamatoyannopoulos G
Am J Hematol; 2006 Dec; 81(12):981-3. PubMed ID: 16888791
[TBL] [Abstract][Full Text] [Related]
20. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
